Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The divestment will allow 30 Technology to accelerate its ultra-broad spectrum NO-generation and rapidly advance its innovative and differentiated platform of NO-generating technologies, including RESP301, a NO-generating liquid designed to release NO in situ.
Lead Product(s): RESP301
Therapeutic Area: Genetic Disease Product Name: RESP301
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: 30 Technology
Deal Size: $218.0 million Upfront Cash: $55.9 million
Deal Type: Divestment April 19, 2023